ROIV
Roivant Sciences Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Roivant Sciences Ltd.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
No other changes.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · May 20 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · May 20 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Roivant Sciences Ltd.
38.23
+2.19 · +6.08%
post 38.14 −0.24%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Roivant Sciences Ltd.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Roivant Sciences Ltd.'s 6 closest co-movers, none share that code.
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $2.9B | 14.06% | +3.90% |
| BlackRockindex-like | $1.7B | 8.37% | +9.00% |
| Morgan Stanley | $1.5B | 7.39% | −17.82% |
| QVT Financial | $839.6M | 4.12% | −5.72% |
| Vanguardindex-like | $782.9M | 3.84% | +6.98% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $2.9B | 14.06% | +3.90% |
| BlackRockindex-like | $1.7B | 8.37% | +9.00% |
| Morgan Stanley | $1.5B | 7.39% | −17.82% |
| QVT Financial | $839.6M | 4.12% | −5.72% |
| Vanguardindex-like | $782.9M | 3.84% | +6.98% |
Bull2
Bear2
Expected move
Inputs8Q avg ±6.6%·×1.32·rich
straddle ±10.1%
spot 38.23exp Nov 20ATM strike 38ATM straddle 4.55IV 71%